Showing 3521-3530 of 7759 results for "".
- Healthy-appearing Lupus Skin Predisposed to Flares, Rasheshttps://practicaldermatology.com/news/healthy-appearing-lupus-skin-predisposed-to-flares-rashes/2461181/Normal-appearing skin of lupus patients contains the same inflammatory signals that are detected when the skin develops a rash – sometimes at even higher levels, according to a study in Science Translational Medicine. “This really starts to piece the puzzle together
- Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Diseasehttps://practicaldermatology.com/news/ready-for-prime-time-ampels-blood-tests-may-predict-drug-options-for-inflammatory-skin-disease/2461179/Ampel BioSolutions machine learning approach can characterize disease activity from gene expression data obtained from patient skin biopsy and may revolutionize the way doctors treat inflammatory skin diseases, according to research published in Science Advances. The lab test
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- New Colorescience, Aesthetics Biomedical Collabhttps://practicaldermatology.com/news/new-colorescience-aesthetics-biomedical-collab/2461177/Colorescience and Aesthetics Biomedical are launching a collaboration that combines Vivace Microneedle RF with a post-treatment protocol featuring Colorescience’s Sunforgettable Total Protection Brush-On Shield SPF 50. Patients opting for the radiofrequency microneedlin
- Chicago Dermatological Society to Host Art of Skin Gala to Advance Diversity, Equity, and Inclusionhttps://practicaldermatology.com/news/chicago-dermatological-society-to-host-art-of-skin-gala-to-advance-diversity-equity-and-inclusion/2461176/The Chicago Dermatological Society (CDS) is launching the Art of Skin Gala, sponsored by Janssen Biotech, Inc. The event, to be held June 10, is described as a live, in color celebration of diversity, equity, and inclusion brought to life through the beauty of skin. The
- Actress Lily Collins is New Living Proof Ambassadorhttps://practicaldermatology.com/news/actress-lily-collins-is-new-living-proof-ambassador/2461174/Actress Lily Collins is the new ambassador for Living Proof. The partnership kicked off with a new brand campaign celebrating its mission of sci
- Dove Survey: Half of All Girls Say Beauty Advice on Social Media Causes Low Self-Esteemhttps://practicaldermatology.com/news/dove-survey-half-of-all-girls-say-beauty-advice-on-social-media-causes-low-self-esteem/2461172/Two in three girls in the US are spending more than an hour each day on social media. Beauty advice fills their feeds, but unfortunately, it is not all positive. In fact, one of two girls say idealized beauty content on social media causes low self-esteem, according to The D
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s
- Milestone Alert: R2 Technologies Ships Out 100 GLACIAL Rx Deviceshttps://practicaldermatology.com/news/milestone-alert-r2-technologies-ships-out-100-glacial-devices/2461169/R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe. To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this mileston
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont